Approximately 80–85% of all lung cancer can be classified as non-small cell lung cancer (NSCLC), of which 3–7% were identified with anaplastic lymphoma kinase (ALK) gene rearranged (referred as ALK-positive) [2, 3]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.